Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

milk25 Dec. 27 at 9:40 PM

$INTS only the patience will make money...lets go!!

0 · Reply

VXRT007 Dec. 27 at 6:15 PM

$INTS waited a very long time for the bottom. everyone thought .40 was the bottom. it has to hold .35

0 · Reply

KingdomCharm Dec. 27 at 3:17 PM

$INTS The setup is defined by credibility, not hype; customer retention trends will be critical to monitor — improving transparency could compress perceived risk. Execution quality is likely to be the main catalyst.

1 · Reply

TenderOfferT Dec. 27 at 5:56 AM

$INTS Sentiment increasingly tracks operational truth rather than guidance tone. Efficiency gains must convert into measurable results. Sustained improvement may validate the long‑term thesis. Without validation, volatility may persist longer than expected.

1 · Reply

TWITLIEDETECTOR Dec. 27 at 2:52 AM

$INTS .35 is safe.

0 · Reply

lamMBD Dec. 26 at 9:35 PM

$INTS Yes, full trading day, bond market half day! Let's just look forward to the new year and making money here!! MBD

0 · Reply

HoldenMeown Dec. 26 at 9:27 PM

$INTS

0 · Reply

lamMBD Dec. 26 at 9:11 PM

$INTS By the way, December 31st is not a full day, only a half day of trading, so it does not count as a full 1 day settlement. Thanks Holden for the dialogue! After forty plus years of investing, you always can learn something! Rules change all the time! If I was interested in selling this close to the end of the year, I would have called and found out exactly what I found out today! Holding my large position in INTS long and strong! Blessings here with your investment in INTS, in the New Year! MBD

0 · Reply

lamMBD Dec. 26 at 9:04 PM

$INTS I just got off the phone with my broker from Charles Schwab. I am INCORRECT! Holden is also INCORRECT from what I was told!! December 30th will be the last day for tax selling. With the new rules, it is no longer 3 days, but a 1 day settlement. In my opinion, most real traders and investors have already sold or previously sold over the last month to do a wash sale, that is, if they want to buy back in two the equity that they sold! Always safe to call your broker for questions and answers! Once again, this is what my broker Charles Schwab told me! Maybe E-Trade is different! MBD

0 · Reply

HoldenMeown Dec. 26 at 8:50 PM

$INTS

0 · Reply

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 7:30 AM EST - 22 days ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 23 days ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Nov 6, 2025, 4:02 PM EST - 7 weeks ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 1:36 PM EDT - 2 months ago

Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript

Oct 31, 2025, 8:00 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Sep 10, 2025, 7:47 AM EDT - 3 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 5 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 8 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 10 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 11 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 1 year ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

$Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023$

Nov 2, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 7, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 5, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

milk25 Dec. 27 at 9:40 PM

$INTS only the patience will make money...lets go!!

0 · Reply

VXRT007 Dec. 27 at 6:15 PM

$INTS waited a very long time for the bottom. everyone thought .40 was the bottom. it has to hold .35

0 · Reply

KingdomCharm Dec. 27 at 3:17 PM

1 · Reply

TenderOfferT Dec. 27 at 5:56 AM

1 · Reply

TWITLIEDETECTOR Dec. 27 at 2:52 AM

$INTS .35 is safe.

0 · Reply

lamMBD Dec. 26 at 9:35 PM

$INTS Yes, full trading day, bond market half day! Let's just look forward to the new year and making money here!! MBD

0 · Reply

HoldenMeown Dec. 26 at 9:27 PM

$INTS

0 · Reply

lamMBD Dec. 26 at 9:11 PM

0 · Reply

lamMBD Dec. 26 at 9:04 PM

0 · Reply

HoldenMeown Dec. 26 at 8:50 PM

$INTS

0 · Reply

alcat1973 Dec. 26 at 8:48 PM

$INTS nothing but selling here. Me, like countless others who bought this when this traded in the top most active Nasdaq after last encouraging pr have been waiting for one fragment of promising news to get this back to 80 cents and beyond where it should be. Meanwhile lots of decision making going on-sell take the loss or just keep waiting and waiting.....

0 · Reply

lamMBD Dec. 26 at 8:43 PM

$INTS Holdenmeow you have no idea what you're talking about!!! Don't know why i'm even wasting my time responding to you with your new profile just this month!! I'm responding to those who are worthy of my response!! Today is the last day for tax selling if you know anything about stock trading and happen to be a REAL investor wchich obviously this HOLDEN person doesn't!!! Just sharing a little knowledge here, that's all! THERE IS A 3 DAY SETTLEMENT WITH ALL EQUITIES!! This does not include weekends/holidays!!! SMH!! MBD

0 · Reply

HoldenMeown Dec. 26 at 3:58 PM

$INTS No, people will selling right up till close on the 31st for tax purposes.

0 · Reply

lamMBD Dec. 26 at 12:21 PM

$INTS Good morning all longs. I hope you all had a wonderful blessed Merry Christmas. Today will be the last day for tax selling. Get ready for a major turnaround. Never looking back at these prices ever!!! MBD

0 · Reply

Zetergius Dec. 25 at 11:19 PM

$INTS holding

0 · Reply

TWITLIEDETECTOR Dec. 25 at 6:21 AM

$INTS still waiting for .35

2 · Reply

igniteyourpassion Dec. 24 at 10:09 PM

$INTS can this revive in the new year and break into double digits https://ca.investing.com/news/stock-market-news/intensity-therapeutics-stock-rises-after-securing-nasdaq-listing-extension-93CH-4351273

0 · Reply

Badnanny Dec. 24 at 5:16 PM

$INTS Just imagine what would happen to our shares if INTS announced a merger with another company. They're looking for funding to restart the trial that's on hold, so anything could happen at anytime 😊 just gotta stay positive. I bought these shares as breast cancer took my mother, her sister has it, and 2 more women in my have had numerous lumps removed, so I believe this drug will be a game changer. Im hoping the big pharmaceutical giants will believe in it too ❤️

1 · Reply

TNNSTrade Dec. 24 at 4:03 PM

$INTS toc tok.... Trials to reusme in early 26 and publication coming... tic toc 👀

2 · Reply

SBEEE Dec. 24 at 12:36 PM

$INTS Another deal another day! https://finance.yahoo.com/m/e64b3f59-9f86-364c-9978-6646e7b313b5/sanofi-to-buy-vaccine-maker.html

0 · Reply

alby777 Dec. 23 at 10:58 PM

$INTS If or when? Merry Christmas, GOD's gift to us!? Our Savior (Jesus) was born!?

0 · Reply

SBEEE Dec. 23 at 10:50 PM

$INTS HAPPY HOLIDAYS!

1 · Reply

Market Cap	24.42M
Revenue (ttm)	0.00
Net Income (ttm)	-16.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	742,500
Avg Vol	36,811,352
Day's Range	N/A - N/A
Shares Out	60.07M
Stochastic %K	27%
Beta	3.58
Analysts	Strong Sell
Price Target	$3.25